<?xml version="1.0" encoding="ISO-8859-1"?>
<BiblioData DataBase="ESPACENET" Version="221" Datum="2012-07-14">
<SubDatabase>
espacenet
</SubDatabase>
<Title>
METHODS OF USING AND CONSTRUCTING NANOSENSOR PLATFORMS
</Title>
<PublicationNumber>
EP2210093A2
</PublicationNumber>
<Inventor>
<Name>
ZHOU CHONGWU [US]
</Name>
<Name>
THOMPSON MARK E [US]
</Name>
<Name>
COTE RICHARD JAMES [US]
</Name>
<Name>
ISHIKAWA FUMIAKI [US]
</Name>
<Name>
CURRELI MARCO [US]
</Name>
<Name>
CHANG HSIAO-KANG [US]
</Name>
<Name>
ZHOU, CHONGWU
</Name>
<Name>
THOMPSON, MARK, E
</Name>
<Name>
COTE, RICHARD, JAMES
</Name>
<Name>
ISHIKAWA, FUMIAKI
</Name>
<Name>
CURRELI, MARCO
</Name>
<Name>
CHANG, HSIAO-KANG
</Name>
</Inventor>
<Applicant>
<Name>
UNIV SOUTHERN CALIFORNIA [US]
</Name>
<Name>
UNIVERSITY OF SOUTHERN CALIFORNIA
</Name>
</Applicant>
<RequestedPatent>
EP2210093
</RequestedPatent>
<ApplicationElem>
<Number>
EP20080867520
</Number>
</ApplicationElem>
<ApplicationDate>
2008-10-01
</ApplicationDate>
<PriorityElem>
<PriorityNumber>
WO2008US78502
</PriorityNumber>
<PriorityDate>
2008-10-01
</PriorityDate>
<PriorityNumber>
US20070976774P
</PriorityNumber>
<PriorityDate>
2007-10-01
</PriorityDate>
<PriorityNumber>
US20070976780P
</PriorityNumber>
<PriorityDate>
2007-10-01
</PriorityDate>
</PriorityElem>
<IPC>
<Class>
G01N33/48
</Class>
</IPC>
<NCL>
<Class>
B82Y15/00
</Class>
<Class>
B82Y30/00
</Class>
<Class>
C12Q1/68B2H
</Class>
<Class>
C12Q1/68B6
</Class>
<Class>
C12Q1/68M6B
</Class>
<Class>
G01N27/414
</Class>
</NCL>
<Abstract>
The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence.
</Abstract>
<Claims>
<P>
CLAIMS
</P>
<P>
1. A method of preparing a nanosensor to detect DNA methylation, comprising: providing a nanosensor; and attaching a probe to the nanosensor, wherein the probe is adapted to bind a methylated DNA sequence.
</P>
<P>
2. The method of claim 1, wherein the nanosensor comprises nanotube and nanowire surfaces.
</P>
<P>
3. The method of claim 1, wherein the nanosensor is an NW/NT sensor.
</P>
<P>
4. The method of claim 1, wherein the probe comprises a polynucleotide.
</P>
<P>
5. The method of claim 1, wherein the probe is adapted to bind an agent.
</P>
<P>
6. The method of claim 5, wherein the agent comprises a signal amplifier.
</P>
<P>
7. The method of claim 1, wherein the probe comprises SEQ. ID. NO.: 1, SEQ. ID. NO.: 2, SEQ. ID. NO.: 3, SEQ. ID. NO.: 4, or a combination thereof.
</P>
<P>
8. The method of claim 1, wherein the probe comprises SEQ. ID. NO.: 5, SEQ. ID. NO.: 6, SEQ. ID. NO.: 7, SEQ. ID. NO.: 8, SEQ. ID. NO.: 9, SEQ. ID. NO.: 10, SEQ. ID. NO.: 11, SEQ. ID. NO.: 12, SEQ. ID. NO.: 13, or a combination thereof.
</P>
<P>
9. A nanosensor for detecting defected DNA, comprising: a NW/NT sensor; and a probe bound thereto, wherein the probe is adapted to bind to a defected DNA.
</P>
<P>
10. The nanosensor of claim 9, wherein the probe is a polynucleotide. 11. The nanosensor of claim 10, wherein the polynucleotide comprises a CG rich sequence.
</P>
<P>
12. The nanosensor of claim 9, wherein the defected DNA comprises a methylated nucleotide.
</P>
<P>
13. The nanosensor of claim 9, wherein the defected DNA comprises a point mutation.
</P>
<P>
14. The nanosensor of claim 9, wherein the probe and defected DNA are adapted to bind as complementary polynucleotides.
</P>
<P>
15. A method of detecting a defected nucleotide in a DNA sample, comprising: providing a nanosensor configured to detectably change when a defected nucleotide bound to a probe on the nanosensor is itself bound by an agent; contacting the nanosensor with a sample; and contacting the nanosensor with the agent, wherein the nanosensor detectably changes if the sample comprises the defected nucleotide.
</P>
<P>
16. The method of claim 15, wherein the agent comprises a methyl-CpG binding protein.
</P>
<P>
17. The method of claim 15, wherein the agent comprises MBDl, MBD2, MBD4 and/or MeCP272.
</P>
<P>
18. The method of claim 15, wherein the agent comprises an antibody.
</P>
<P>
19. The method of claim 15, wherein the defected nucleotide comprises a point mutation.
</P>
<P>
20. The method of claim 15, wherein the agent comprises a DNA repair protein. 21. The method of claim 15, wherein the defected nucleotide comprises a methylated DNA nucleotide.
</P>
<P>
22. A method of diagnosing a disease in an individual in which the presence or absence of methylation for a plurality of genetic loci is associated with the disease, comprising: using a nanosensor to determine the presence or absence in the individual of the methylation in the plurality of genetic loci; and diagnosing the individual as having the disease if the individual demonstrates the presence or absence of the methylation of the plurality of genetic loci.
</P>
<P>
23. The method of claim 22, wherein the disease is cancer.
</P>
<P>
24. A method of treating a disease in an individual in which the presence or absence of methylation for a plurality of genetic loci is associated with the disease, comprising: using a nanosensor to determine the presence or absence in the individual of the methylation in the plurality of genetic loci; diagnosing the individual as having the disease if the individual demonstrates the presence or absence of the methylation of the plurality of genetic loci; and treating the disease, if the individual is diagnosed as having it.
</P>
<P>
25. The method of claim 24, wherein the disease is cancer.
</P>
<P>
CLAIMS
</P>
<P>
1. A method of preparing a nanosensor to detect DNA methylation, comprising: providing a nanosensor; and attaching a probe to the nanosensor, wherein the probe is adapted to bind a methylated DNA sequence.
</P>
<P>
2. The method of claim 1, wherein the nanosensor comprises nanotube and nanowire surfaces.
</P>
<P>
3. The method of claim 1, wherein the nanosensor is an NW/NT sensor.
</P>
<P>
4. The method of claim 1, wherein the probe comprises a polynucleotide.
</P>
<P>
5. The method of claim 1, wherein the probe is adapted to bind an agent.
</P>
<P>
6. The method of claim 5, wherein the agent comprises a signal amplifier.
</P>
<P>
7. The method of claim 1, wherein the probe comprises SEQ. ID. NO.: 1, SEQ. ID. NO.: 2, SEQ. ID. NO.: 3, SEQ. ID. NO.: 4, or a combination thereof.
</P>
<P>
8. The method of claim 1, wherein the probe comprises SEQ. ID. NO.: 5, SEQ. ID. NO.: 6, SEQ. ID. NO.: 7, SEQ. ID. NO.: 8, SEQ. ID. NO.: 9, SEQ. ID. NO.: 10, SEQ. ID. NO.: 11, SEQ. ID. NO.: 12, SEQ. ID. NO.: 13, or a combination thereof.
</P>
<P>
9. A nanosensor for detecting defected DNA, comprising: a NW/NT sensor; and a probe bound thereto, wherein the probe is adapted to bind to a defected DNA.
</P>
<P>
10. The nanosensor of claim 9, wherein the probe is a polynucleotide. 11. The nanosensor of claim 10, wherein the polynucleotide comprises a CG rich sequence.
</P>
<P>
12. The nanosensor of claim 9, wherein the defected DNA comprises a methylated nucleotide.
</P>
<P>
13. The nanosensor of claim 9, wherein the defected DNA comprises a point mutation.
</P>
<P>
14. The nanosensor of claim 9, wherein the probe and defected DNA are adapted to bind as complementary polynucleotides.
</P>
<P>
15. A method of detecting a defected nucleotide in a DNA sample, comprising: providing a nanosensor configured to detectably change when a defected nucleotide bound to a probe on the nanosensor is itself bound by an agent; contacting the nanosensor with a sample; and contacting the nanosensor with the agent, wherein the nanosensor detectably changes if the sample comprises the defected nucleotide.
</P>
<P>
16. The method of claim 15, wherein the agent comprises a methyl-CpG binding protein.
</P>
<P>
17. The method of claim 15, wherein the agent comprises MBDl, MBD2, MBD4 and/or MeCP272.
</P>
<P>
18. The method of claim 15, wherein the agent comprises an antibody.
</P>
<P>
19. The method of claim 15, wherein the defected nucleotide comprises a point mutation.
</P>
<P>
20. The method of claim 15, wherein the agent comprises a DNA repair protein. 21. The method of claim 15, wherein the defected nucleotide comprises a methylated DNA nucleotide.
</P>
<P>
22. A method of diagnosing a disease in an individual in which the presence or absence of methylation for a plurality of genetic loci is associated with the disease, comprising: using a nanosensor to determine the presence or absence in the individual of the methylation in the plurality of genetic loci; and diagnosing the individual as having the disease if the individual demonstrates the presence or absence of the methylation of the plurality of genetic loci.
</P>
<P>
23. The method of claim 22, wherein the disease is cancer.
</P>
<P>
24. A method of treating a disease in an individual in which the presence or absence of methylation for a plurality of genetic loci is associated with the disease, comprising: using a nanosensor to determine the presence or absence in the individual of the methylation in the plurality of genetic loci; diagnosing the individual as having the disease if the individual demonstrates the presence or absence of the methylation of the plurality of genetic loci; and treating the disease, if the individual is diagnosed as having it.
</P>
<P>
25. The method of claim 24, wherein the disease is cancer.
</P>
</Claims>
<Also_published_as>
WO2009046110A1;WO2009085356A2;WO2009085356A3;WO2009085356A8;WO2009046136A2;WO2009046136A3;US2010260745A1;US2011275544A1;US2010292348A1;JP2011518311A;EP2205714A1;EP2205714A4;CN102016570A;CA2701447A1;CA2701401A1;CA2701380A1
</Also_published_as>
</BiblioData>
